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Background: Genomic analysis of multi-focal renal cell carcinomas from an individual with a germline VHL
mutation offers a unique opportunity to study tumor evolution.
Results: We perform whole exome sequencing on four clear cell renal cell carcinomas removed from both kidneys
of a patient with a germline VHL mutation. We report that tumors arising in this context are clonally independent
and harbour distinct secondary events exemplified by loss of chromosome 3p, despite an identical genetic
background and tissue microenvironment. We propose that divergent mutational and copy number anomalies are
contingent upon the nature of 3p loss of heterozygosity occurring early in tumorigenesis. However, despite distinct
3p events, genomic, proteomic and immunohistochemical analyses reveal evidence for convergence upon the
PI3K-AKT-mTOR signaling pathway. Four germline tumors in this young patient, and in a second, older patient with
VHL syndrome demonstrate minimal intra-tumor heterogeneity and mutational burden, and evaluable tumors
appear to follow a linear evolutionary route, compared to tumors from patients with sporadic clear cell renal cell
carcinoma.
Conclusions: In tumors developing from a germline VHL mutation, the evolutionary principles of contingency and
convergence in tumor development are complementary. In this small set of patients with early stage VHL-associated
tumors, there is reduced mutation burden and limited evidence of intra-tumor heterogeneity.Background
Von Hippel-Lindau (VHL) disease is an autosomal domin-
ant hereditary cancer syndrome attributed to germline
mutation of the VHL gene, located on chromosome 3p25
[1,2]. The clinical phenotype is characterized by the devel-
opment of vascular tumors, including hemangioblastomas
of the central nervous system and retina, clear cell renal
cell carcinomas (ccRCCs) and pheochromocytomas. In* Correspondence: charles.swanton@cancer.org.uk
†Equal contributors
1Cancer Research UK London Research Institute, London WC2A 3LY, UK
3University College London Cancer Institute, London WC1E 6DD, UK
Full list of author information is available at the end of the article
© 2014 Fisher et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.the kidney, loss of the remaining wild-type VHL allele,
consistent with a ‘two-hit’ model of tumor suppressor in-
activation [3], results in multiple pre-neoplastic cysts and
ccRCC tumors. In sporadic ccRCC, somatic mutation or
hypermethylation of VHL occurs in the majority [4-6] and
3p loss of heterozygosity (LOH) in over 90% of cases
[6-8]. Furthermore, recent work from our group has dem-
onstrated that 3p LOH and VHL mutation or methylation
are early truncal (ubiquitous) events in 10 of 10 cases of
sporadic ccRCC subjected to multi-region sequencing
(M-seq) [9]. Biallelic inactivation of the tumor suppressor
gene VHL is therefore established as an early event intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ccRCC [6,8-11].
Next-generation DNA sequencing has identified an
additional set of tumor suppressor genes that are recur-
rently mutated in sporadic ccRCC [6,7,11-14]. Several of
these (PBRM1, SETD2 and BAP1) are also located on
chromosome 3p, emphasizing the importance of this locus
for ccRCC tumorigenesis. A second striking feature of this
catalogue of somatic events is that tumor suppressor genes
involved in chromatin modification, including PBRM1,
SETD2, KDM6A and JARID1C [15], and components
of the phosphoinositide 3 kinase (PI3K)-AKT-mammalian
target of rapamyocin (mTOR) pathway (for example,
PTEN, PIK3CA, AKT, TSC1/2 and MTOR), feature prom-
inently. Whole exome sequencing of multiple regions of
primary ccRCC has shown that anomalies in these genes
may occur subclonally, separated spatially within the same
primary tumor. Despite profound intra-tumor hetero-
geneity, parallel evolution of subclones occurs with con-
vergence of distinct mutations occurring in the same
gene, signal transduction pathway or protein complex
[9,11], within a branched evolutionary model of cancer
development [16]. It is evident that the branching pat-
tern of mutational events in ccRCC (and other cancers)
is highly complex, and varies significantly between pa-
tients with the same histopathological tumor type [9].
Importantly, cancer cells do not evolve in isolation but
in the context of the tissue eco-system. Selection can
therefore be influenced by multiple environmental factors
(reviewed in [17,18]).
The genomic analysis of synchronous or metachronous
tumors occurring in the same organ in one individual of-
fers a rare opportunity to relate evolutionary principles to
tumorigenesis. Cancers that develop from an identical
germline abnormality, arising in the same organ, and
that are subject to the same environmental constraints
are analogous to a hypothetical experiment proposed by
the paleontologist and evolutionary biologist Stephen
Jay Gould. Gould summarized his view of the history of
life and multi-cellular organism evolution by challen-
ging that if the ‘tape of life’ were to be re-wound to the
same starting point and re-played under the same con-
ditions, the evolutionary trajectory would follow a
markedly different course to the one actually taken [19].
This does not imply that evolution is random, but rather
that the final result is causally dependent upon the se-
quence of antecedent steps, a notion Gould termed
‘historical contingency’. Convergence, or the idea that
evolutionary constraint results in a limited set of out-
comes, may be cited as an opposing theory to contin-
gency [20]. Here we use whole exome sequence data
from a patient with a germline VHL mutation and syn-
chronous ccRCC tumors to add experimental evidence
for contingency, but also find that contingency andconvergence are not mutually exclusive but rather com-
plementary. We propose that in this patient, the devel-
opment of independent primary kidney cancers in the
context of a germline VHL mutation occurs by a differ-
ent sequence of genomic abnormalities in each tumor,
contingent upon the nature of a chromosome 3p LOH
event occurring early in tumorigenesis. Ultimately, however,
the tumor trajectories converge to cause PI3K-AKT-mTOR
pathway activation, via somatic mutation of components
of this pathway and alternative mechanisms. Surprisingly,
in contrast to 10 sporadic ccRCCs from older patients,
the three assessable tumors follow linear, rather than
branched, evolutionary routes and have few somatic
mutations. We suggest this is due to the consequence of
the young age and early tumor stage at diagnosis, follow-
ing cyst surveillance due to the germline VHL syndrome,
allowing limited time for acquisition of passenger muta-
tions and subclonal expansion, contributing to spatial
heterogeneity.
Results
Clinical case report
A 32-year-old male presented with hematuria. Ultrasound
demonstrated multiple renal cysts and the initial diagnosis
was polycystic kidney disease. However, the cysts enlarged
during a surveillance period of one year, leading to com-
puted tomography imaging demonstrating a locally ad-
vanced right renal tumor, and two tumors in the left
kidney (Figure 1). Further investigation revealed capillary
retinal angiomas and hemangiomas of the brain and spine
typical of VHL disease, and he was diagnosed with a de
novo, germline nonsense mutation in exon 3 of the
VHL gene. At the age of 33, the patient underwent a
radical right nephrectomy; histopathological examin-
ation confirmed a single stage 3, Fuhrman grade 3 ccRCC
(pT3aN0M0). Six months later, there was progression in
the left kidney and he was treated with partial left neph-
rectomy to remove both tumors. Both were stage 1 ccRCCs
with a maximum Fuhrman grade of 2 (pT1aN0M0). At
the time of this report, the patient remains in complete
remission.
Whole exome sequencing defines four tumors of
independent clonal origin
We harvested multiple regions from each tumor on the
right and left sides, as well as normal kidney tissue,
attempting to sample the spatial extent and morphological
heterogeneity of each renal cell carcinoma. Whole exome
sequencing (WES) to a median depth of 87× was per-
formed on seven tumor regions from the right side
(representing one morphological tumor with a heterogenous
macroscopic appearance), and on nine tumor regions from
the left side (representing two, macroscopically distinct but
homogenous tumors). We used the CaVEMan algorithm to
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2 4
3
1
A) B)
Figure 1 Multi-focal renal cell carcinoma tumors in a patient with VHL disease. Coronal sections from computed tomography scans show the
spatial orientation of the tumors within the kidneys. (A) A macroscopically single tumor in the right kidney, but defined by exome sequencing as two
tumors (one and two). (B) Two separate tumors in the left kidney, tumors three and four. Cysts typical of VHL disease are also present in both kidneys.
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against germline DNA extracted from peripheral blood and
sequenced to a depth of 94×. Small insertions and deletions
(indels) were identified using Pindel, described previously
[9]. All candidate mutations were subjected to orthogonal
validation by ultra-deep amplicon sequencing, to an average
depth of 254×. A non-synonymous mutation or indel was
verified if the variant allele occurred in at least 1% of reads.
A nonsense mutation was confirmed at codon 120,
exon 3 (R120*) in the VHL gene, present in the blood,
normal kidney tissue and all tumor regions. All tumor
regions also displayed 3p LOH, which we have previ-
ously found to be the only common early event in spor-
adic clear cell renal tumorigenesis together with VHL
mutation or methylation [9]. In addition, WES identified
97 non-synonymous mutations, including 11 indels, present
in at least one tumor region. Validation was attempted for
all 97 putative mutations; 16 variants did not validate (val-
idation rate 83.5%). Validation data for a further 15 vari-
ants were considered inconclusive, either because an
amplicon could not be generated or there was insufficient
read coverage (<50×) and these were excluded from fur-
ther analysis. The spatial distribution of validated somatic
mutations clearly defined four, rather than three, tumors
of distinct clonal origin (two on each side) - hereafter referred
to as tumors one and two on the right side and three and
four on the left side (Figure 2; Additional file 1: Table S1).
Parallel tumor evolution and distinct 3p LOH events in
each of the four ccRCC tumors
We determined the tumor ploidy of each region by flow
cytometry and implemented ABSOLUTE [21] to estimatecopy number aberrations (CNAs) in each of the tumor re-
gions. We observed ubiquitous 3p LOH in all tumor biop-
sies from this patient, consistent with this being an early
founder event common to all clear cell carcinomas [9]
(Figure 3A; Additional file 2).
However, we identified four distinct CNA profiles de-
fined by differing breakpoint locations in chromosome
3p and additional CNAs; these four profiles correspond
to the four distinct tumors delineated by somatic muta-
tion analysis (Figure 3B). For tumor one from the right
kidney, the chromosome 3p breakpoint mapped to CLRN1.
However, in the ipsilateral tumor two, the breakpoint fell
in the vicinity of ALCAM. Additionally, tumors one and
two differ by their loss of 6q and gain of 5q, respectively.
On the left side, tumor three demonstrated loss of 3p with
a breakpoint in the centromere as well as gain of 2q. Com-
paratively, the copy number profile in tumor four was
complex and was suggestive of genome doubling. This
was confirmed by flow cytometry assessment of ploidy,
demonstrating that tumor four was near-tetraploid with a
DNA index of 1.82 (Additional file 3). The 3p breakpoint
in tumor four mapped to the region of BFSP2, and there
were a number of additional events, including gains of
chromosomes 2, 5, 7, 9, 10, 12, 16 and 17.
Phylogenetic tree analysis reveals distinct, linear
evolutionary trajectories of hereditary VHL ccRCCs
We defined a driver event as a somatic mutation in a
gene or CNA previously reported to occur in ccRCC
[6,7,9,11-13,22]. Each non-synonymous mutation was
assigned a category of 1 to 3 according to published
criteria (category 1, high confidence driver mutation;
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Figure 2 Intra-tumor heterogeneity in four germline tumors. (A,B) Heatmaps show the regional distribution of all non-silent mutations;
presence (blue) or absence (grey) of each mutation is indicated for every tumor region in tumors from the right (A) and left kidneys (B). Whole
exome sequencing defines four distinct tumors. In each, tumor evolution is linear rather than branched.
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of unknown significance) [9]. Apart from 3p LOH, som-
atic driver events differed between the four tumors delin-
eated by WES (Figure 2). For example, in the right kidney,
somatic mutations were identified in ARID1A in tumor
one (category 2), and in IDH2 in tumor two (category 3).
In tumors three and four, there was a distinct somatic mu-
tation in MTOR (categories 2 and 3, respectively) in each
tumor, and PBRM1 and KDM6A and NRAS mutations (all
category 3) in tumor three. Subsequent to VHL mutation
and loss of 3p, no single copy number or mutational event
was common to all four tumors, suggesting contingency
and the unpredictable nature of tumor evolution subse-
quent to a similar germline event.Intriguingly, in contrast to sporadic clear cell carcin-
omas, intra-tumor heterogeneity (ITH) in germline-
associated tumors in this patient was not profound and
linear, rather than branched, evolution appears to occur
in at least two of the four tumors (tumors two and
three) in this young patient subjected to renal surveil-
lance. In the stage 1 tumor three from the left kidney,
93% (14/15) of somatic mutations and copy number
events were ubiquitous (present in all seven tumor re-
gions). The remaining somatic mutation in RAB11FIP1
was shared by five of seven tumor regions. In the stage 3
tumor two on the right side, 81% (13/16) of mutations
and copy number events were ubiquitous, and 19% (3/16)
heterogenous. However, among the three mutations that
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Figure 3 Copy number analysis in four germline tumors. (A) Copy number profiles of representative samples from each of the four tumors, with
integer copy number on the x-axis. Loss of chromosome 3p is ubiquitous. (B) The chromosome 3p breakpoint locations for the four tumors. Each y-axis
is logR, and the x-axis represents position along chromosome 3 in hg19. An ‘X’ near the x-axis marks the approximate position of the centromere.
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branching between spatially separated tumor biopsies, con-
sistent with a linear model of tumor evolution.
We calculated an index of branch to truncal mutations
(ITB) for assessable tumors by dividing the mean numberof non-ubiquitous mutations by the total number of
ubiquitous mutations per tumor biopsy, and compared
the indices for this patient with those of sporadic ccRCC
tumors analyzed by M-seq previously [9] (Table 1). In
this young patient with germline VHL mutant tumors,
Table 1 Branch:trunk indices (ITB) from M-seq for
germline VHL mutant and sporadic ccRCC tumors
Tumor code Age of
patient
(years)
Germline or
sporadic VHL
mutation/methylation
Tumor stage ITB
Tumor 3 (left) 33 Germline I 0.06
EV006 65 Sporadic IV 0.07
EV003 64 Sporadic IV 0.17
Tumor 2 (right) 33 Germline III 0.19
EV007 59 Sporadic IV 0.56
RMH008 64 Sporadic III 0.64
EV002 59 Sporadic IV 0.67
EV005 79 Sporadic IV 0.75
EV001 75 Sporadic IV 0.84
RMH002 63 Sporadic IV 0.93
RMH004 61 Sporadic IV 1.81
RK26 47 Sporadic II 2.35
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fall within the low end of the range in this small cohort.
Reduced mutational load in germline VHL tumors
We defined the mutational load of a tumor as the num-
ber of non-synonymous somatic mutations per tumor
biopsy; in this patient, the median mutational load in the
stage 1 and stage 3 tumors was 13 (range 13 to 23). We
hypothesized that the few somatic mutations observed
in this patient, compared with a large cohort reported by
The Cancer Genome Atlas (TCGA) [6], was a conse-
quence of lower tumor stage and/or the young age at
presentation. To further investigate this, we performed
WES, to a median depth of 86x, on two samples of a
homogeneous stage 1 ccRCC removed from a male pa-
tient aged 67 years with VHL syndrome (Additional file 4).
Average life expectancy in VHL syndrome is only 49 years
with renal cell carcinoma the leading cause of mortality
[23]; therefore, ccRCC tumors from patients with a com-
parable age to the median age of diagnosis in sporadic
ccRCC (63 years) are only rarely available. We confirmed
a germline VHL mutation, as well as loss of 3p and gain of
5q in both tumor regions. Surprisingly, the mutation bur-
den in this older patient was also low; we validated 26
non-synonymous somatic mutations of 33 candidate mu-
tations (validation rate 78.8%; Additional file 5). Of these
26 mutations, 25 (96%) were shared by both tumor re-
gions. We could not identify a known ccRCC driver gene
in the tumor biopsies from this second patient (Additional
file 1: Table S2). Furthermore, there was a striking absence
of somatic mutations in chromosome 3p genes in tumors
from both VHL syndrome patients. This is in clear con-
trast to the somatic mutation spectrum observed in the
cohort of sporadic ccRCC patients with locally advancedand/or metastatic tumors, all of which demonstrated
branched evolution and harbored multiple somatic muta-
tions in genes located on chromosome 3 [9,11]. It is note-
worthy that these somatic events almost always occurred
in the branches, and were therefore subclonal. For ex-
ample, all the SETD2 and BAP1 somatic mutations and
the majority of PBRM1 mutations were found in the
branches of the tumor phylogenetic trees. In contrast, the
tumors from our syndromic VHL patients reported in this
manuscript do not demonstrate branched evolution. We
speculate that the absence of branched evolution and sub-
clonal diversification is the reason we fail to see second
hits in SETD2, BAP1 and PBRM1 in our study. Alterna-
tively, the different patterns of driver mutations observed
between syndromic and sporadic ccRCC may relate to renal
surveillance and the removal of early versus late stage tu-
mors, respectively, and conceivably, mutations in one or
more of these genes may themselves drive branched evolu-
tion and tumor progression.
Convergence upon the PI3K-AKT-mTOR pathway
The two tumors in the left kidney harbored distinct
point mutations in the MTOR gene (tumor three, p.
L2427P; tumor four, p.T1652A). While only the first of
these occurred in an identical amino acid encoded by a
described alteration in MTOR [24-26], we predicted both
to be hyper-activating based on their locations in the
kinase and FAT (FRAP-ATM-TRAAP) domains of the
mTOR protein, respectively, according to published
studies [24-29] (Figure 4). However, after transfection of
HEK-293 T cells with complementary DNA plasmids en-
coding wild-type or mutant (L2427P and T1652A) mTOR,
only the L2427P mutant induced phosphorylation of S6K
(Additional file 6). Phosphorylation of the other mTOR
substrate, 4E-BP1, was similar between the wild-type, kin-
ase domain and FAT domain mutant cells. These results
confirm that the kinase domain mutation L2427P activates
mTORC1 signaling, but suggest that the second mutation
in the FAT domain, T1652A, does not. Indeed, T1652A is
not reported elsewhere as a recurrent or functionally sig-
nificant mutation; however, highly activating FAT domain
mutations have been reported with experimental evidence
suggesting that these may effect mTOR pathway activa-
tion by reducing binding between Deptor and mTOR [26].
We used a multi-array and Meso-Scale Discovery
(MSD) technology to detect and quantify the levels of
phosphorylated and non-phosphorylated intracellular kin-
ase proteins of the PI3K-AKT-mTOR pathway. In all
tumor regions, there was evidence of either S6K or 4EPB1
phosphorylation, consistent with pathway activation, rela-
tive to normal kidney from each side (Figure 5). In par-
ticular, S6K was phosphorylated in the tumor regions
harboring the L2427P MTOR mutation. Additionally, im-
munohistochemical analysis of the mTOR substrates S6K
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FRB domain
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Figure 4 Two distinct activating mutations in mTOR. Left: a schematic of the mTOR protein structure (cyan) in complex with mLST8 (dark
blue) (PDB code 4JSP). Key residues and structural features are highlighted close to mTOR mutations relevant to the current study. The FRB and
FAT domains are also labeled together with the FATC sub-domain. Right: a close-up of regions in proximity to the mTOR mutation site L2427
abutting the nucleotide-binding cleft and activation loop (upper right panel). Lower right panel shows the environment surrounding residue
T1652 in the FAT domain.
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staining of either or both substrates relative to normal
kidney in a pattern consistent with the proteomic data
(Additional file 1: Table S3; Additional file 7). This is in
contrast to absent staining of S6K and 4E-BP1 in MTOR
wild-type tumor regions in a ccRCC previously reported
[11]. We conclude that all tumors displayed functional
convergence of mTOR pathway activation, despite dis-
tinct evolutionary somatic routes. Tumor four (harbor-
ing the FAT domain mutation) demonstrated markedly
elevated phosphorylation of AKT, to a similar extent as
induced in tumor three (harboring the kinase domain
mutation). However, in tumor four there was increased
phosphorylation of 4E-BP1 but not of S6K. Absent S6K
phosphorylation would appear to be consistent with
the lack of an activating mutation in mTOR in this re-
gion described earlier. There is evidence indicating
that 4E-BP1 is regulated independently of S6K and it
remains unclear whether the effect of AKT signaling
on 4E-BP1 is wholly integrated by mTOR, or alterna-
tive kinases [30,31].Similarly, in both tumors from the right kidney, without
mutations in MTOR, there was increased phosphorylation
of both S6K and 4E-BP1 substrates. However, phosphoryl-
ation of AKT or mTOR proteins relative to normal kidney
tissue did not occur in tumors one and two. We propose
that pathway activation in these tumors occurred by alter-
native mechanisms to MTOR mutation or AKT activation;
mutation in ARID1A [32] or amplification of target genes
on chromosome 5q, such as GNB2L1 and SQSTM1
[33-35], are both plausible explanations. Tumor two
harbored a mutation in PIK3C2A, encoding the class II
PI3K-C2α enzymes; the role of this enzyme in cell sig-
naling and cell survival has been debated [36], but the
most recent evidence indicates that it does not activate
AKT [37]. In addition, mutations in PIK3C2A reported
in cancer samples are distributed evenly across the
protein and do not recurrently affect specific residues,
suggesting these are passenger events [22].
Mutations in genes encoding components of the PI3K
pathway and in ARID1A are reported at low frequencies
in ccRCC (up to 6% and 3%, respectively) [6]. However,
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EGFR, PTEN, PIK3CA, AKT, TSC1/2, RHEB, and MTOR
co-occur less frequently than would be expected by
chance, as reported previously [6]. Further analysis reveals
that mutations in ARID1A, MTOR, TSC1 and TSC2 show
a similarly strong tendency towards mutual exclusivity
(Additional file 8) and provides additional support for the
role of ARID1A mutations in convergent activation of the
PI3K pathway.
In summary, the proteomic and immunohistochemis-
try data illustrate clear convergence upon the PI3K-
AKT-mTOR pathway, with increased signaling of the
downstream substrates S6K and 4E-BP1, consistent with
pathway activation in all tumors relative to normal kid-
ney tissue. The mechanisms by which pathway activation
occurred differed between tumors from the left and right
kidneys and are likely to have been determined by dis-
tinct mutational or copy number events in each. In tu-
mors without mutations in genes known to impact upon
PI3K pathway signaling, we propose that alternative and
as yet unknown mechanisms cause pathway activation
based on substantial evidence for the integration of mul-
tiple regulatory inputs [31] and complex layers of con-
trol of the TORC1 complex, including the influence of
the FAT domain mutation in the MTOR gene.
Discussion
We report novel whole-exome sequencing data derived
from metachronous, bilateral ccRCC tumors in a patient
with VHL disease. Multi-focal tumors developing fromthe same germline, and in the same organ, are of inde-
pendent clonal origin in this patient, despite identical
histopathological characterization. Furthermore, genomic
analysis reveals the presence of two distinct tumors in the
right kidney, from what appeared macro- and microscopic-
ally to be a single ccRCC tumor. Our findings are consist-
ent with an earlier report of copy number variation in 36
germline VHL mutant primary ccRCC tumors; within each
of 12 patients, metachronous tumors displayed different
copy number profiles, to the extent that tumors from the
same patient were as dissimilar to each other as they were
to tumors from other patients with VHL disease [38].
This clinical situation allows a rare insight into tumor
evolution from the VHL mutant germline state in ccRCC,
where the initiating event is the same across multiple tu-
mors within the same organ and similar microenviron-
ments; the combination of somatic mutation and copy
number data defines a unique series of abnormalities for
each of the four tumors. It is evident that, from a common
starting point, there are multiple, currently unpredictable,
routes to tumor development. Mutation of VHL was as-
sumed to be the first hit, because of its presence in the
germline in blood and normal kidney tissue. Based on pre-
vious data establishing that chromosome 3p loss is one of
the founder events in ccRCC [8,9], and the ubiquitous
nature of this event within the four tumors subjected to
M-seq in this study, 3p LOH is likely to be the second hit.
However, copy number data indicate that even amongst
tumors arising from the same germline and in an identical
environment, each of the four tumors harbored a distinct
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of a different second event in the four tumors is to drive
each through divergent trajectories; thus, subsequent
events might be contingent upon the nature of the 3p
event in these tumors. The notion that the final result of
evolution is determined by antecedent steps is consistent
with Gould’s theory of historical contingency. Of course, it
is possible that an alternative driver event, such as 5q gain
or somatic mutation, was the contingent step; however, on
the basis that the 3p LOH is the only other ubiquitous
event observed in sporadic cases and is ubiquitous in all
tumors studied here, this is also likely to be one of the
earliest events in VHL syndrome clear cell carcinoma.
Gould used the re-interpretation of the fossils of the
Burgess Shale to illustrate an alternative view of life’s
history, and offered the term contingency to encompass
the idea of evolution as a series of unpredictable and un-
repeatable events, but a system in which the final out-
come is causally dependent on the occurrence of each
antecedent step [19]. Gould referred to the concept of
historical constraints within a lineage that limit the abil-
ity of natural selection to modify the future lineage; this
notion of internal selective factors is cited by others in
the field of developmental biology [39,40]. Our results
support these statements by showing that histologically
similar tumors derived from germline VHL mutation
share 3p LOH as the second event but are then distin-
guished by their subsequent somatic genomic events.
However, there may be constraints to their evolution,
exemplified by the activation of the mTOR pathway in
all tumor regions.
Naturally occurring or experimental evidence to sup-
port Gould’s claim of historical contingency is limited
[41,42]. The molecular analysis of acute lymphoblastic
leukemia in monozygotic twins provides support for his
ideas [43-45]. Two separate twin studies now show that
while the initiating event of a chromosomal fusion (even
if not inherited) is the same, subsequent genomic aberra-
tions differ substantially between cases of concordant
and discordant acute lymphoblastic leukemia within
monozygotic twin pairs, and this may have a profound
bearing on clinical outcome. A second example from
cancer medicine is in myelodysplastic syndromes, in
which early driver mutations in different genes have
been shown to direct disease evolution down ‘preferred’
trajectories, resulting in distinct clinical phenotypes [46].
In a simply designed long-term evolution experiment
using 12 identical populations of Escherichia coli estab-
lished in 1988, Lenski and colleagues managed to re-play
the ‘evolutionary tape’ and thus provide unique evidence
for historical contingency [47,48]. Further evidence for
the evolution of specific protein functions being contin-
gent upon permissive, ancestral mutations has been re-
ported recently [49]. Results from our observational datasupport similar themes illustrated by these experiments:
the development of a particular phenotype from an iden-
tical cell population and environment occurs via diverse,
multi-step evolutionary pathways.
Conway Morris argued that evolution is constrained to
such a degree that it converges upon a restricted range
of options [20]. In this case, despite parallel evolution of
the four individual tumors, there is indeed evidence for
convergence upon the PI3K-AKT-mTOR pathway with
two independent MTOR mutations in tumors from the
left kidney and proteomic evidence for pathway activa-
tion in all tumor regions. Our data add to a compelling
body of evidence for convergence upon this pathway, both
within and between individual patients. A recent analysis
of 106 ccRCC cases reported that the MTOR gene was
mutated in nearly 6% of cases, but that a quarter of
cases harbored mutations in genes encoding signaling
molecules in the PI3K-AKT-mTOR cascade, including
PTEN, PIK3CA, TSC1 and TSC2 [7]. Furthermore, the
proportion of pathway mutations rises to 60% when
calculated on a per patient, rather than per biopsy,
basis [9].
Functional convergence on the mTOR pathway was
evidenced by phosphorylation of downstream substrates
S6K or 4E-BP1 in all four tumors relative to normal kid-
ney, despite divergent somatic copy number and muta-
tional events. In vitro experiments showed that the
mutation in the FAT domain of mTOR was not activat-
ing; the functional significance of this mutation there-
fore remains unclear but theoretically it could influence
mTOR-substrate interactions. It is likely that similar micro-
environmental selection pressures across all four tumors
contribute significantly to convergent signaling activity wit-
nessed in this study. The identification of an ARID1Amuta-
tion in tumor one in the contralateral kidney to those
tumors harboring MTOR mutations may further illus-
trate convergence upon the PI3K-AKT-mTOR pathway.
Co-occurrence of mutations of this gene and those of
the PI3K pathway are reported to occur in endometrial
and head and neck cancers, and ARID1A mutations may
impact upon PI3K pathway activity [32,50]. Although
the mechanism is unknown, phosphorylation of PI3K
downstream targets, including PDK1, AKT, TSC2 and
S6K, was significantly upregulated in the presence of
ARID1A mutations, and knockdown of wild-type ARID1A
in three endometrial cancer cell lines resulted in signifi-
cantly elevated phosphorylation of AKT [32]. Pathway acti-
vation in tumor two could have been the result of gain of
chromosome 5q, which has been identified as a driver in
ccRCC, occurring in 67% of samples [6]. Importantly, gain
of amplicon 5q.35.3 results in alteration of two genes,
GNB2L1 and SQSTM1, whose overexpression is associ-
ated with activation of the PI3K pathway [6,33-35]. It is
noteworthy that mutations in MTOR and in GNB2L1 and
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[6], consistent with pathway convergence as demonstrated
by tumors one/two and three/four in this patient. Further-
more, we observed a strong tendency towards mutual ex-
clusivity between mutations in ARID1A and PI3K pathway
genes (MTOR and TSC1/2) [6]. In summary, we suggest
that dysregulation of the PI3K pathway in this patient was
achieved in all tumors but mediated by diverse mutational
or copy number events.
In two patients with ccRCC tumors arising from germ-
line VHL mutation, ITH was minimal despite extensive
sampling in both a morphologically heterogeneous stage
3 tumor and a morphologically homogeneous stage 1
tumor. Within one of these patients, two evaluable tu-
mors appeared to follow a linear, rather than branched
evolutionary path. Furthermore, there was a noticeable
absence of mutations in driver ccRCC genes, or second
hits, in genes such as SETD2, PBRM1 and BAP1 in both
patients. These patterns, distinct from those observed in
tumors from patients with sporadic ccRCC, might be a
direct consequence of a critical mutational event in the
germline. Alternatively, early stage, non-metastatic dis-
ease may harbor less genetic ITH than advanced later
stage tumors, although our recent cohort of sporadic
ccRCCs included one stage 2 and one stage 3 tumor and
both demonstrated ITH and branched evolution; in par-
ticular, the high ITB index for the stage 2 tumor testifies
to this [9]. Further assessment of spatial ITH in early
stage, node-negative, sporadic and germline VHL mutant
tumors will be required to formally test these hypotheses.
Conclusions
In germline VHL mutant ccRCC, historical contingency
is illustrated by a different 3p LOH event in each of four
clonally distinct tumors together with distinct driver
events in each of the four tumors. Despite independent
evolutionary trajectories, structural genomic and somatic
events, selected within a similar microenvironment, con-
verge to cause activation of the PI3K-AKT-mTOR path-
way. Through the analysis of spatially and temporally
separate ccRCC tumors from a young patient with germ-
line VHL mutation, these data highlight the complemen-
tary properties of contingency and convergence during
tumor evolution within an identical genetic background
and tissue microenvironment.
Materials and methods
Patient samples
The patients consented to provide blood and tissue sam-
ples and clinical information, in a study approved by the
National Research Ethics Committee London (Fulham,
reference number 11/LO/1996) and the study was con-
ducted in accordance with the principles of the Declaration
of Helsinki. Both patients provided written consent topublication of the study results. At the time of neph-
rectomy surgery, samples of tumor tissue and normal
kidney were collected according to strict protocols
published previously [11]. For the first patient, from
the right nephrectomy specimen, approximately 1 cm
of tumor was taken from seven distinct regions, represent-
ing the spatial extent of the tumor and morphological het-
erogeneity. From the left partial nephrectomy specimen,
two separate tumors were dissected from the kidney and
provided whole. The first tumor was bisected and one
half divided into eight regions. The second tumor was
amorphous due to significant disruption during the sur-
gical process and was processed as one sample. For the
second patient, the largest tumor was bisected. Each
tumor region was dissected using a fresh scalpel to avoid
DNA contamination between samples, and all samples
were snap-frozen within 60 minutes of ischemia. From
each region, a matched sample was taken for histopatho-
logical assessment.
Whole exome sequencing
DNA was extracted from blood and tissue samples using
the Qiagen DNeasy kit and the manufacturer’s protocol
(Manchester, United Kingdom The Beijing Genomics In-
stitute performed initial quality control assessments, and
then exome capture using the Agilent Human All Ex-
ome V4 kit (Cheshire, United Kingdom). Samples were
paired-end multiplex sequenced on the Illumina HiSeq
platform to a median target depth of >100×. Tumors
from the second patient were sequenced at the London
Research Institute, using the same methodology but on
rapid runs.
Data availability
Exome sequencing data have been deposited in the
European Genome-phenome Archive under accession
number EGAS00001000907.
Bioinformatics analysis
We received paired-end reads from the Beijing Genomics
Institute in FastQ files, which underwent initial quality
control before alignment to the human genome hg19.
Coverage levels of aligned files were assessed before and
after removal of positional duplicates. Exome capture was
performed to an average coverage of 86× and 85× for the
right-sided and left-sided tumors, respectively. Somatic
single nucleotide variants (SNVs) were detected using the
CaVEMan algorithm and germline DNA from blood as
the normal reference. A set of post hoc filters [9] was then
applied to the putative variant calls and the resulting list
manually reviewed on the Integrated Genome Viewer [51]
to remove variants in poorly aligned reads or those with
profiles characteristic of sequencing errors [52]. Sequen-
cing data from normal tissue from both kidneys acted as
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tissue were compared; however, no mutations apart
from that in VHL were identified in normal tissue. Variants
were annotated as synonymous or non-synonymous using
both dbNSFP [53] and Annovar [54] . Small insertions and
deletions were identified using a modified version of Pindel
software and methods published previously [9,12,55].
Validation
We created custom Ampliseq (Lifetech, Paisley, United
Kingdom) validation panels by entering genomic posi-
tions of all non-synonymous somatic mutations and
indels called in at least one region into the Ion AmpliSeq
Designer [56] (150 bp amplicon size option selected).
Multiplex PCRs were performed according to the manu-
facturer’s instructions with the tumor-specific primer
pool on DNA from each region of the tumors. Amplicon
pools were used for the construction of barcoded se-
quencing libraries and these were multiplex sequenced
with 200 bp read length on the Ion Torrent PGM se-
quencer, to a mean target depth of 500× (Lifetech).
Ploidy profiling
A suspension of nuclei was created from fresh tumor tissue
and washed with phosphate-buffered saline (PBS), then
fixed with 70% ethanol. After 60 minutes, nuclei were
washed again with PBS and stained with propidium iodide.
Flow cytometric analysis of DNA content was performed
using the BD LSRFortessa Cell Analyzer, BDFacsDiva™
software and FlowJo software (Oxford, United Kingdom
and Ashland, Oregon, United States. The DNA index of
the aneuploid peak, where present, was calculated by divid-
ing the G1 peak of the aneuploid population by the G1
peak of the normal diploid cells.
Copy number analysis
Raw copy number estimates were generated from Illumina
exome sequencing data using VarScan2 (v2.2.11) with de-
fault parameters except for the data-ratio parameter,
which was calculated as in [57]. Low mapability regions
(segmental duplications and ENCODE ‘DAC blacklisted’
regions, as annotated by the UCSC genome browser) and
the sex chromosomes were excluded. Raw log2-ratio
(logR) calls were adjusted for GC content and quantile
normalized. Outliers were detected and modified using
Median Absolute Deviation Winsorization prior to
patient-specific joint segmentation (gamma = 1,000)
[58], to identify genomic segments of constant logR.
To calculate absolute (integer) copy numbers from the
relative copy number data, tumor purity and ploidy were
estimated using ABSOLUTE (v1.0.6) [21]. The analysis
incorporated somatic nucleotide variants with variant al-
lele frequencies (VAF) >5% and >50x coverage identified
using Caveman that were independently validated and/or unlikely to represent technical artifacts (as determined
by varSLR, which models strand bias, mapping quality,
base quality and position-in-read in a stepwise logistic re-
gression framework Minimum/maximum ploidy was set
to within ±0.5 of the prior ploidy estimate, calculated from
the sample’s fluorescence-activated cell sorting (FACS)-
based DNA index. To identify an optimal ABSOLUTE
model for a given sample, the top five ABSOLUTE models
(ranked by log-likelihood) were retrieved. Subsequently, a
set of inter-sample models was identified that minimized
the total pairwise distance derived from the segments’ ex-
pected modal copy number and SNV multiplicity, whilst
maximizing the models’ posterior log likelihoods, using
rank aggregation (Cross-Entropy method) as implemented
in the RankAggreg package [59]. Final model solutions
were manually reviewed as recommended (v1.0.6) [21].
Having identified optimal models that fit the relative
copy number data, adjacent segments of equal clonality
and absolute copy number were merged. LogR plots
were annotated with the locations of recurrent copy
number changes referenced in the TCGA Copy Number
Portal [60]. ABSOLUTE was also used to assess the
clonality of SNVs and SCNAs, as specified in [61]
(Pr(CCF < 0.95) < 0.5).
To calculate the mirrored B-allele frequency (mBAF),
candidate heterozygous SNPs with >40× coverage in the
tumor samples were identified in the reference sample
using VarScan2, and then filtered by Gaussian mixture
model-based clustering using the mclust package [62].
ABSOLUTE-derived purity estimates were used to adjust
mBAF, as described by Van Loo et al. [63]. In order to
identify segments of significant allelic imbalance, the
mBAF distributions within a segment between reference
and tumor sample were compared using the Wilcoxon
signed rank test with subsequent Bonferroni correction.
mTOR catalytic domain structure modeling
The location of mTOR mutations was mapped using the
structure of a large mTOR fragment bound to mLST8
(PDB code 4JSP) and the figure was prepared using the
graphics program PYMOL [64].
Co-transfection assays
We plated 1.8 × 106 HEK-293 T cells per well in six-well
tissue culture plates, transfected 24 hours later with
Flag-mTOR encoding plasmids (1,500 ng) and HA-S6K
encoding plasmid (50 ng) using Lipofectamine 2000 (Life
Technologies, New York, New York, United States).
Twenty-four hours post-transfection, cells were starved in
Hanks Balanced Salt Solution for 1 hour, stimulated in
Dulbecco’s modified Eagle medium supplemented with
10% fetal bovine serum for 1 hour, and followed by whole
cell lysis in RIPA buffer (50 mM Tris pH 7.5, 150 mM
NaCl, 0.1% SDS, 1% Triton X-100, Protease inhibitor
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and Phosphotase inhibitor cocktail (Millipore, Billerica,
Massachusetts, United States).
Whole cell lysates (30 mg) were mixed with NuPAGE
LDS Sample Buffer (4X; Life Technologies), heated in
70°C for 10 minutes, loaded into lanes of NuPAGE 4-12%
Bis-Tris Protein Gels (Life Technologies), run at 120 volts
for 2 hours in 1× MOPS buffer (Life Technologies) and
transferred to 0.45 mm PVDF membrane at 100 volts
for 1 hour in 1× transfer buffer (25 mM Tris, 192 mM
glycine, 20% methanol).
All primary antibodies were diluted 1:1,000 in 1% milk
w/v phosphate-buffered saline Tween (PBST), and all
secondary antibodies were diluted 1:5,000 in 1% milk
w/v PBST. Antibodies were detected using the enhanced
Chemiluminescence method (Western Lighting, Perkin
Elmer, Waltham, Massachusetts, United States). Immu-
noblot signals were acquired with the LAS-3000 Imaging
system (FujiFilm).
Primary antibodies used were p-p70S6K(Thr389),
p70S6K, p-4E-BP1(Thr70), 4E-BP1, Raptor (Cell Signal-
ing, Ozyme, France), Flag-M2 (Sigma, St Louis, Missouri,
United States). pRK7-HA-S6K1-wt was a gift from the
Neal Rosen lab. pcDNA3-Flag-mTOR wt was acquired
from Addgene (Cambridge, Massachusetts, United States).
MTOR point mutations were generated in pcDNA3-
Flag-mTOR wt using site-directed mutagenesis with the
QuikChange II XL kit according to the manufacture’s
protocol (Agilent, Santa Clara, California, United States).
Primer sequences were: L2427P_F:catcagcctccagttcgg
caaggggtcatagac; L2427P_R:gtctatgaccccttgccgaactggaggct
gatg; T1652A_F:cttgagccaggctctcatgtcttcatgagggct; T1652
A_R: agccctcatgaagacatgagagcctggctcaag.
Assessment of the phosphokinome
Whole proteins were extracted from each of the four tu-
mors and from two normal kidney samples. The levels of
total and phosphorylated forms of intracellular kinases
Akt/p-Akt, mTOR/p-mTOR, p70S6K/p-p70S6K and 4E-
BP1/p-4E-BP1 were measured using MSD® (Rockville,
MD 20850, US) immunoassay technology. Assays were
performed by coating 96-well microplates (MSD) with
10 μg/well of whole protein lysates from tumor or cell
samples and incubation with the following primary anti-
bodies: Akt, p-Akt (Ser473), p-Akt (Thr308), mTOR,
p-mTOR (Ser2448), p70S6K, p-p70S6K (Thr389), 4E-BP1
and p-4E-BP1 (Thr70) (Cell Signaling). Plates were then
washed with PBS-T and incubated with SULFO-TAG anti-
rabbit or anti-mouse antibodies (MSD) as secondary de-
tection antibody for 1 hour at room temperature. The
signal was detected using a SECTOR® Imager 2400 in-
strument (MSD) and the results expressed in electro-
chemiluminescence counts. The signal for each sample
signal was adjusted for its corresponding GAPDH value.The human serum signal (background) for each of the
corresponding antibodies was subtracted. An alternative
ratio of phosphorylated to total protein was calculated
for each spot, to yield four values for a given sample and
a given protein, and then bootstrapping applied to iden-
tify the most robust value.Immunohistochemistry
Rabbit anti-phospho-S6 ribosomal protein (Ser235/236)
and rabbit anti-phospho-4E-BP1 antibodies (Thr37/46)
(Cell Signaling: #2211, #2855), were used for immunohis-
tochemistry on paraffin sections. Antigens were unmasked
by microwaving in Tris-EDTA pH9 (pS6) and citrate pH6
(4E-BP1) and incubated with primary antibodies at 1:50
(pS6) and 1:800 (p4E- BP), respectively. After incubation
in biotinylated secondary antibody and 14Avidin Biotin
Complex, slides were developed in DAB substrate (all
from Vector, Peterborough, United Kingdom). Staining
for pS6 and p4E-BP1 was scored by one pathologist (GS)
and grouped into three categories based on staining inten-
sity and frequency [65]: 0, less than 10% of cells with weak
staining; 1, more than 10% of cells with weak staining or
less than 20% of cells with strong staining; 2, more than
20% of cells with strong staining.Additional files
Additional file 1: Table S1. Validated non-synonymous mutations for
each tumor. Table S2. Validated non-synonymous mutations in tumor in
patient 2. Table S3. Immunohistochemical analysis of all tumor regions
for phosphorylated S6K and 4E-BP1. Tumor staining for each region was
assigned a category of 0 (<10% of cells with weak staining), 1 (>10% of
cells with weak staining or <20% of cells with strong staining) or 2 (>20%
of cells with strong staining).
Additional file 2: Figure S1. Copy number profiles for all tumor
regions of a young patient with VHL syndrome and multi-focal ccRCC
tumors.
Additional file 3: Figure S2. Ploidy profiles for four distinct tumors,
confirming genome doubling in tumor four with a DNA index of 1.82.
Additional file 4: Figure S3. Clinical photographs from partial
nephrectomy for a stage 1 ccRCC in a 67-year-old patient with VHL
syndrome. The tumor was located in the lower anterior pole of the right
kidney and was bisected to give two tumor regions.
Additional file 5: Figure S4. Heatmap showing validated non-
synonymous mutations in a morphologically homogeneous tumor from
a 67-year-old patient with VHL syndrome. The presence (blue) or absence
(grey) of each mutation is indicated for tumor regions 1 and 2.
Additional file 6: Figure S5. Kinase mutant induces S6K1
phosphorylation. HEK-293 T cells were co-transfected with HA-S6K and
mTOR wt or mutant cDNA plasmids. Twenty-four hours later, cells were
nutrient-deprived for 1 hour, nutrient-stimulated for 1 hour, followed by
whole cell lysis. The lysates were then immunoblotted for the indicated
proteins and phosphorylation states of S6K1 and 4E-BP1.
Additional file 7: Figure S6. Representative slides demonstrating
positive staining for S6K and 4E-BP1 in tumors 2 and 3. (A) S6K staining
of tumor two at 10× magnification, (B) 4E-BP1 staining of tumor two at
40× magnification, (C) S6K staining of tumor three at 10× magnification,
and (D) 4E-BP1 staining of tumor three at 10× magnification.
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http://genomebiology.com/2014/15/8/433Additional file 8: Figure S7. Mutual exclusivity analysis showing a
strong tendency towards mutual exclusivity of mutations in ARID1A,
MTOR, TSC1 and TSC2. Each grey bar represents one tumor biopsy
reported by the TCGA (image cropped and magnified; dataset analysed
included 417 tumor samples). Mutations in MTOR, PIK3CA, ARID1A, PTEN,
TSC1 and TSC2 are indicated by green bars. Figure generated using cBio
cancer genomics portal.
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